8-K: GT Biopharma Receives FDA Clearance for GTB-3650 IND, Plans Phase 1 Trial

GT Biopharma announced FDA clearance for its Investigational New Drug application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial.

Summary

• GT Biopharma has received FDA clearance for its Investigational New Drug (IND) application for GTB-3650, a NK cell engager for the treatment of CD33+ leukemia.
• The company plans to initiate a Phase 1 clinical trial for GTB-3650 in the second half of 2024, with initial clinical data expected in the first half of 2025.
• GT Biopharma also anticipates submitting an IND application for GTB-5550, targeting B7H3 positive solid tumors, in the first quarter of 2025.
• A Phase 1 dose escalation basket trial for GTB-5550 is expected to begin in 2025, evaluating its effectiveness in six solid tumor cancers.
• The company expects its current cash runway to be sufficient to fund operations into 2025.
• GTB-3650 will be evaluated in up to six cohorts of adult patients with relapsed or refractory CD33 expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
• The trial will assess safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity.
• The company will become a fully remote company effective July 1, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA clearance and the planned clinical trials. The company's progress in its pipeline and the anticipated cash runway contribute to a favorable outlook.

Positives

• FDA clearance of the IND application for GTB-3650 is a significant milestone for the company.
• The initiation of a Phase 1 trial for GTB-3650 in the second half of 2024 is a positive step forward.
• The expected submission of the IND application for GTB-5550 in Q1 2025 indicates continued progress in the pipeline.
• The planned Phase 1 dose escalation basket trial for GTB-5550 in 2025 will explore multiple solid tumor indications.
• The company's cash runway is expected to be sufficient to fund operations into 2025, providing financial stability.

Risks

• The company's forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially.
• Clinical trials are subject to inherent risks, including the possibility of unexpected adverse events or lack of efficacy.
• The company's ability to successfully develop and commercialize its therapies is dependent on various factors, including regulatory approvals and market acceptance.

Future Outlook

The company plans to initiate a Phase 1 trial for GTB-3650 in the second half of 2024, submit an IND for GTB-5550 in Q1 2025, and start a basket trial for GTB-5550 in 2025. The company anticipates its cash runway will fund operations into 2025.

Management Comments

• Michael Breen, Executive Chairman and Interim CEO, stated that the FDA clearance for GTB-3650 is a tremendous accomplishment.
• Michael Breen also mentioned the company's plans to submit an IND for GTB-5550 in the first quarter of 2025.
• Michael Breen noted that the trial design for GTB-3650 should provide an early read on safety and potential therapeutic activity.

Industry Context

This announcement is significant in the immuno-oncology space, as GT Biopharma is advancing its TriKE platform, which is designed to harness and enhance the cancer-killing abilities of a patient's own natural killer (NK) cells. The company is targeting both hematologic malignancies and solid tumors, which are areas of high unmet medical need.

Comparison to Industry Standards

• The development of NK cell engagers is a growing area in immuno-oncology, with companies like Fate Therapeutics and Nkarta also pursuing similar approaches.
• GT Biopharma's TriKE platform is unique in its design, incorporating an interleukin (IL)-15 moiety for NK cell survival and proliferation.
• The planned Phase 1 trials for GTB-3650 and GTB-5550 are consistent with the typical development pathway for novel therapeutics.
• The company's focus on both hematologic malignancies and solid tumors is aligned with the broader industry trend of exploring multiple cancer indications.

Stakeholder Impact

• Shareholders will likely view the FDA clearance and planned clinical trials positively.
• Employees may be impacted by the transition to a fully remote company.
• Patients with CD33+ leukemia and solid tumors may benefit from the development of these therapies.
• The company's suppliers and partners may see increased activity as clinical trials progress.

Next Steps

• Initiate Phase 1 clinical trial for GTB-3650 in the second half of 2024.
• Submit IND application for GTB-5550 in the first quarter of 2025.
• Start Phase 1 dose escalation basket trial for GTB-5550 in 2025.
• Continue to pursue additional opportunities for various autoimmune indications.

Key Dates

Keywords

GT Biopharma, FDA, IND, GTB-3650, GTB-5550, TriKE, NK cell engager, clinical trial, immuno-oncology, leukemia, solid tumors, AML, MDS